TY - JOUR T1 - Predictors of mortality in cancer patients requiring intensive care support: Two-centered cohort study JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P1994 AU - Dursun Tatar AU - Özlem Yazicioglu Moçin AU - Pinar Cimen AU - Zuhal Karakurt AU - Cenk Kirakli AU - Gökay Güngör AU - Ozlem Ediboglu AU - Nalan Adiguzel AU - Emel Tellioglu AU - Cuneyt Salturk AU - Merih Balci Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P1994.abstract N2 - Aim: Acute respiratory failure (ARF) can be developed in cancer patients due to disease progression or as a complication of treatment. In our study we aimed to identify the factors associated with mortality in cancer patients admitted to the intensive care unit (ICU) due to ARF.Method: A retrospective-cohort study was planned in two ICUs of training hospital of chest diseases between January 2008 and december 2011 period. Demographic data, type of cancer, cause of ARF, comorbid disease, APACHE II value, type of treatment, and mortality were recorded from the medical records of cancer patients followed in ICU.Results: During the study period 463 (373 male) cancer patients were included in the study followed by two-centers in the ICU. The median age of the patients was 65 (57-72). 78 % of the patients were lung cancer while 22 % of the patients were extrapulmonary cancer and the mortality rates were similar. Cause of ARF in 84 % (n:391) of the patients were due to cancer invasion and 12 % was infections. APACHE II value was 24 (18-30) and and ICU day was 5 (2-10). Application of invasive and noninvasive mechanical ventilation was respectively 20% and 74%. The mortality rate of the cancer patients in ICU was 54 %. APACHE II value was significantly higher in patients who were died (p<0.001). The mortality of the female patients were higher (p<0.05).Conclusion: The mortality is higher than the overall ICU mortality, in patients with advanced cancer who required ICU support. In our study; APACHE II value and female gender are the marker of high mortality in cancer patients developed ARF. ER -